Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Amylyx Pharmaceuticals, Inc. (AMLX)
USD17.41
-0.36 (-2.03%)
US NASDAQ Healthcare Biotechnology
Address
43 Thorndike Street 2141
Cambridge, MA, US
Cambridge, MA, US
CEO
Joshua Cohen
Website
amylyx.com
IPO
2022-01-07
CIK 1658551 ISIN US03237H1014
Description
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD17.41
-0.36 (-2.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
-0.16
Float Shares
55.26M
Free Float %
66.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.96% | -5.00% | -12.33% | +2.27% | +16.26% | +19.54% | +221.60% | -48.69% | -20.09% | -20.09% | -20.09% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
17.41
Low
21.00
+20.6%
Consensus
24.50
+40.7%
Median
24.50
+40.7%
High
28.00
+60.8%
DCF (Unlevered)
2.30
-86.8%
DCF (Levered)
2.33
-86.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
92% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 11 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
21.00
+20.6%
|
| Last Quarter | 3 |
22.67
+30.2%
|
| Last Year | 7 |
20.71
+19.0%
|
| All Time | 16 |
12.63
-27.5%
|
Quality scores
Altman Z-Score
31.98
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+65.5% ★ Q1'26: +11.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +17,942.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+38.8% Q1'26: +29.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 7 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 8 Rev. Ana. 6 EPS Ana. |
Dec 2029 7 Rev. Ana. 4 EPS Ana. |
Dec 2030 7 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 528.3K (-100.0%)
|
22.23M
est: 4.42M (+402.7%)
|
380.79M
est: 398.00M (-4.3%)
|
87.37M
est: 88.03M (-0.7%)
|
—
est: 114.53M (-100.0%)
|
80.6K
16.3K – 173.7K
-99.9% YoY
|
44.69M
16.87M – 73.55M
+55,323.5% YoY
|
153.24M
153.24M – 153.24M
+242.9% YoY
|
321.42M
64.98M – 692.42M
+109.7% YoY
|
538.32M
108.83M – 1.16B
+67.5% YoY
|
| EBITDA |
-82.64M
est: -200.3K (-41,163.7%)
|
-200.85M
est: -1.68M (-11,881.7%)
|
39.89M
est: 8.34M (+378.4%)
|
-290.98M
est: 1.84M (-15,877.1%)
|
-144.16M
est: 2.40M (-6,107.9%)
|
1.7K
341.00 – 3.6K
-99.9% YoY
|
936.2K
353.5K – 1.54M
+55,330.3% YoY
|
3.21M
3.21M – 3.21M
+242.9% YoY
|
6.73M
1.36M – 14.51M
+109.7% YoY
|
11.28M
2.28M – 24.30M
+67.5% YoY
|
| EBIT |
-82.69M
est: -200.6K (-41,127.5%)
|
-201.34M
est: -1.68M (-11,892.6%)
|
38.80M
est: 8.11M (+378.4%)
|
-291.88M
est: 1.79M (-16,369.9%)
|
-144.69M
est: 2.33M (-6,298.8%)
|
1.6K
332.00 – 3.5K
-99.9% YoY
|
910.7K
343.9K – 1.50M
+55,327.9% YoY
|
3.12M
3.12M – 3.12M
+242.9% YoY
|
6.55M
1.32M – 14.11M
+109.7% YoY
|
10.97M
2.22M – 23.63M
+67.5% YoY
|
| Net Income |
-87.93M
est: -1.05B (+91.6%)
|
-198.38M
est: -237.86M (+16.6%)
|
49.27M
est: -71.10M (+169.3%)
|
-301.74M
est: -406.36M (+25.7%)
|
-144.74M
est: -150.11M (+3.6%)
|
-137.08M
-154.58M – -119.58M
+8.7% YoY
|
-147.88M
-167.61M – -71.83M
-7.9% YoY
|
-83.04M
-83.30M – 24.16M
+43.8% YoY
|
55.32M
-2.06M – 138.33M
+166.6% YoY
|
183.77M
-6.83M – 459.53M
+232.2% YoY
|
| SGA |
38.93M
est: 3.35M (+1,062.6%)
|
127.13M
est: 28.03M (+353.5%)
|
188.36M
est: 757.95M (-75.1%)
|
114.33M
est: 167.64M (-31.8%)
|
62.89M
est: 218.11M (-71.2%)
|
153.5K
31.0K – 330.8K
-99.9% YoY
|
85.10M
32.13M – 140.07M
+55,323.8% YoY
|
291.84M
291.84M – 291.84M
+242.9% YoY
|
612.11M
123.75M – 1.32B
+109.7% YoY
|
1.03B
207.26M – 2.21B
+67.5% YoY
|
| EPS |
-1.52
est: -15.35 (+90.1%)
|
-2.98
est: -3.49 (+14.6%)
|
0.73
est: -1.05 (+169.3%)
|
-4.43
est: -4.33 (-2.3%)
|
-1.53
est: -1.55 (+1.4%)
|
-1.43
-1.63 – -1.26
+7.9% YoY
|
-1.29
-1.77 – -0.76
+9.9% YoY
|
-0.59
-0.88 – 0.26
+54.4% YoY
|
0.59
-0.02 – 1.46
+199.6% YoY
|
1.94
-0.07 – 4.86
+232.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-28 | Mizuho | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-120.47M
OE per share TTM
-1.24
Owner's Yield
-7.17%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
24
Total invested
6.61M
Insider transactions (90d)
0
Beneficial owners (>5%)
31
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David C. Ott | 7.17M | 12.40% | — | 7.17M | — | 7.17M | IN | Delaware | 2022-01-21 | ↗ |
| 2 | O. Andreas Halvorsen | 7.17M | 12.40% | — | 7.17M | — | 7.17M | IN | Delaware | 2022-01-21 | ↗ |
| 3 | Rose S. Shabet | 7.17M | 12.40% | — | 7.17M | — | 7.17M | IN | Delaware | 2022-01-21 | ↗ |
| 4 | Viking Global Investors LP | 7.17M | 12.40% | — | 7.17M | — | 7.17M | PN | Delaware | 2022-01-21 | ↗ |
| 5 | Viking Global Opportunities GP LLC | 7.17M | 12.40% | — | 7.17M | — | 7.17M | OO | Delaware | 2022-01-21 | ↗ |
| 6 | Viking Global Opportunities Parent GP LLC | 7.17M | 12.40% | — | 7.17M | — | 7.17M | OO | Delaware | 2022-01-21 | ↗ |
| 7 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 4.87M | 8.40% | — | 4.87M | — | 4.87M | PN | Delaware | 2022-01-21 | ↗ |
| 8 | Viking Global Opportunities Portfolio GP LLC | 4.87M | 8.40% | — | 4.87M | — | 4.87M | OO | Delaware | 2022-01-21 | ↗ |
| 9 | Chen Yu | 4.64M | 6.80% | — | 4.64M | — | 4.64M | IN | Delaware | 2024-08-26 | ↗ |
| 10 | TCG Crossover Fund II, L.P. | 4.64M | 6.80% | — | 4.64M | — | 4.64M | PN | Delaware | 2024-08-26 | ↗ |
| 11 | TCG Crossover GP II, LLC | 4.64M | 6.80% | — | 4.64M | — | 4.64M | OO | Delaware | 2024-08-26 | ↗ |
| 12 | Joseph Edelman | 4.46M | 6.50% | — | 4.46M | — | 4.46M | IN | Delaware | 2024-10-25 | ↗ |
| 13 | Perceptive Advisors LLC | 4.46M | 6.50% | — | 4.46M | — | 4.46M | IA | Delaware | 2024-10-25 | ↗ |
| 14 | Perceptive Life Sciences Master Fund, Ltd. | 4.46M | 6.50% | — | 4.46M | — | 4.46M | CO | Delaware | 2024-10-25 | ↗ |
| 15 | The Vanguard Group - 23-1945930 | 4.36M | 6.58% | — | — | 35.4K | 50.8K | IA | Pennsylvania | 2023-02-09 | ↗ |
| 16 | James Huang | 4.20M | 6.20% | — | 4.20M | — | 4.20M | IN | Cayman Islands | 2024-03-11 | ↗ |
| 17 | Panacea Innovation Limited | 4.20M | 6.20% | — | 4.20M | — | 4.20M | CO | Cayman Islands | 2024-03-11 | ↗ |
| 18 | Panacea Venture Healthcare Fund II GP Company, Ltd. | 4.20M | 6.20% | — | 4.20M | — | 4.20M | CO | Cayman Islands | 2024-03-11 | ↗ |
| 19 | Panacea Venture Healthcare Fund II, L.P. | 4.20M | 6.20% | — | 4.20M | — | 4.20M | PN | Cayman Islands | 2024-03-11 | ↗ |
| 20 | (1) BlackRock, Inc. | 4.00M | 5.90% | 3.95M | — | 4.00M | — | HC | Delaware | 2024-01-29 | ↗ |
| 21 | GOLDMAN SACHS & CO. LLC | 3.65M | 5.40% | — | 3.65M | — | 3.65M | BD, IA, OO | Delaware | 2023-06-09 | ↗ |
| 22 | THE GOLDMAN SACHS GROUP, INC. | 3.65M | 5.40% | — | 3.65M | — | 3.65M | HC, CO | Delaware | 2023-06-09 | ↗ |
| 23 | Steven A. Cohen | 3.47M | 5.10% | — | 3.47M | — | — | IN | United States | 2023-12-11 | ↗ |
| 24 | Point72 Asset Management, L.P. | 3.18M | 4.70% | — | 3.18M | — | — | PN | Delaware | 2023-12-11 | ↗ |
| 25 | Point72 Capital Advisors, Inc. | 3.18M | 4.70% | — | 3.18M | — | — | CO | Delaware | 2023-12-11 | ↗ |
| 26 | 2 | 2.97M | 5.10% | — | 2.97M | — | 2.97M | IA | Delaware | 2022-06-21 | ↗ |
| 27 | DRAGSA 96 LLC | 2.30M | 4.00% | — | 2.30M | — | 2.30M | OO | Delaware | 2022-01-21 | ↗ |
| 28 | Israel A. Englander | 1.62M | 2.80% | — | 1.62M | — | 1.62M | IN | — | 2022-09-21 | ↗ |
| 29 | Millennium Group Management LLC | 1.62M | 2.80% | — | 1.62M | — | 1.62M | OO | — | 2022-09-21 | ↗ |
| 30 | Millennium Management LLC | 1.62M | 2.80% | — | 1.62M | — | 1.62M | OO | — | 2022-09-21 | ↗ |
| 31 | Cubist Systematic Strategies, LLC | 294.6K | 0.40% | — | 294.6K | — | — | OO | Delaware | 2023-12-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
24
-166 vs prev Q
New positions
6
Closed positions
162
Increased
11
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 44.2K +44.2K (+100.0%) | 534.21M +534.2M (+100.0%) | 0.05% +0.047 pp | 0.47% +0.467 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 2 | FMR LLC | 16.52M +5.1M (+45.2%) | 199.54M +44.9M (+29.0%) | 17.70% +4.933 pp | 0.01% +0.002 pp | USD11.61 +4.0% | 16 qtrs — |
| 3 | BLACKROCK, INC. | 9.05M +1.9M (+26.8%) | 109.38M +12.3M (+12.7%) | 9.70% +1.690 pp | 0.00% +0.000 pp | USD8.07 +49.7% | 6 qtrs — |
| 4 | PERCEPTIVE ADVISORS LLC | 8.28M -667.5K (-7.5%) | 100.08M -21.6M (-17.7%) | 8.88% -1.167 pp | 1.78% -1.729 pp | USD4.78 +152.7% | 16 qtrs — |
| 5 | TCG CROSSOVER MANAGEMENT, LLC | 6.24M +— (+0.0%) | 75.43M -9.4M (-11.1%) | 6.69% -0.315 pp | 2.50% -1.678 pp | USD3.80 +217.9% | 6 qtrs — |
| 6 | VANGUARD GROUP INC | 5.80M +531.2K (+10.1%) | 70.12M -1.5M (-2.2%) | 6.22% +0.303 pp | 0.00% 0.000 pp | USD16.00 -24.5% | 16 qtrs — |
| 7 | COMMODORE CAPITAL LP | 5.65M +1.6M (+38.6%) | 68.25M +12.9M (+23.2%) | 6.05% +1.482 pp | 4.54% +1.840 pp | USD13.17 -8.3% | 2 qtrs — |
| 8 | SATURN V CAPITAL MANAGEMENT LLC | 4.50M -108.4K (-2.4%) | 54.32M -8.3M (-13.2%) | 4.82% -0.348 pp | 9.97% -3.756 pp | USD7.04 +71.6% | 5 qtrs — |
| 9 | JANUS HENDERSON GROUP PLC | 4.47M +1.9M (+76.1%) | 53.99M +19.5M (+56.7%) | 4.78% +1.940 pp | 0.02% +0.008 pp | USD12.94 -6.6% | 2 qtrs — |
| 10 | FIRST LIGHT ASSET MANAGEMENT, LLC | 3.36M -343.0 (0.0%) | 40.53M -5.1M (-11.1%) | 3.60% -0.170 pp | 3.10% -1.200 pp | USD13.59 -11.1% | 2 qtrs — |
| 11 | DRIEHAUS CAPITAL MANAGEMENT LLC | 3.11M +688.7K (+28.5%) | 37.56M +4.7M (+14.2%) | 3.33% +0.616 pp | 0.26% +0.020 pp | USD10.33 +16.9% | 3 qtrs — |
| 12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.78M -4.0M (-59.3%) | 33.55M -59.1M (-63.8%) | 2.98% -4.672 pp | 0.05% -0.096 pp | USD4.55 +165.5% | 4 qtrs — |
| 13 | GOLDMAN SACHS GROUP INC | 2.61M +602.6K (+30.0%) | 31.57M +4.2M (+15.5%) | 2.80% +0.544 pp | 0.00% +0.001 pp | USD12.88 -6.2% | 14 qtrs — |
| 14 | MORGAN STANLEY | 2.36M +409.5K (+21.0%) | 28.51M +2.0M (+7.6%) | 2.53% +0.341 pp | 0.00% +0.000 pp | USD14.41 -16.2% | 16 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 2.17M +353.5K (+19.5%) | 26.16M +1.5M (+6.2%) | 2.32% +0.287 pp | 0.00% +0.000 pp | USD11.25 +7.4% | 16 qtrs — |
| 16 | ALMITAS CAPITAL LLC | 2.12M +— (+0.0%) | 25.64M -3.2M (-11.1%) | 2.27% -0.107 pp | 5.65% -0.957 pp | USD2.04 +492.2% | 7 qtrs — |
| 17 | STATE STREET CORP | 2.07M +448.6K (+27.7%) | 25.00M +3.0M (+13.5%) | 2.22% +0.399 pp | 0.00% +0.000 pp | USD10.52 +14.8% | 16 qtrs — |
| 18 | GREAT POINT PARTNERS LLC | 1.75M +50.0K (+2.9%) | 21.14M -2.0M (-8.5%) | 1.88% -0.032 pp | 6.85% -2.673 pp | USD4.05 +198.3% | 4 qtrs — |
| 19 | 683 CAPITAL MANAGEMENT, LLC | 1.65M -110.0K (-6.3%) | 19.93M -4.0M (-16.7%) | 1.77% -0.207 pp | 0.87% -0.382 pp | USD2.48 +387.1% | 7 qtrs — |
| 20 | EVENTIDE ASSET MANAGEMENT, LLC | 1.51M +648.0 (+0.0%) | 18.28M -2.3M (-11.1%) | 1.62% -0.076 pp | 0.29% -0.052 pp | USD13.59 -11.1% | 2 qtrs — |
| 21 | BANK OF AMERICA CORP /DE/ | 1.34M +906.5K (+211.1%) | 16.14M +10.3M (+176.5%) | 1.43% +0.950 pp | 0.00% +0.001 pp | USD9.63 +25.4% | 16 qtrs — |
| 22 | DEUTSCHE BANK AG\ | 1.33M -32.3K (-2.4%) | 16.11M -2.5M (-13.2%) | 1.43% -0.103 pp | 0.01% -0.001 pp | USD13.92 -13.2% | 16 qtrs — |
| 23 | FRANKLIN RESOURCES INC | 1.20M +1.2M (+100.0%) | 14.50M +14.5M (+100.0%) | 1.29% +1.286 pp | 0.00% +0.004 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 24 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 1.00M -103.0K (-9.3%) | 12.13M -2.9M (-19.4%) | 1.08% -0.166 pp | 0.03% -0.016 pp | USD5.87 +105.8% | 10 qtrs — |
| 25 | LOGOS GLOBAL MANAGEMENT LP | 950.0K -500.0K (-34.5%) | 11.48M -8.2M (-41.8%) | 1.02% -0.609 pp | 0.69% -1.073 pp | USD13.59 -11.1% | 2 qtrs — |
| 26 | NORTHERN TRUST CORP | 937.8K +115.5K (+14.1%) | 11.33M +154.0K (+1.4%) | 1.00% +0.082 pp | 0.00% +0.000 pp | USD9.08 +33.0% | 16 qtrs — |
| 27 | ADAR1 CAPITAL MANAGEMENT, LLC | 890.4K +24.2K (+2.8%) | 10.76M -1.0M (-8.6%) | 0.95% -0.018 pp | 0.79% -0.316 pp | USD3.77 +220.4% | 9 qtrs — |
| 28 | BALYASNY ASSET MANAGEMENT L.P. | 858.7K -617.6K (-41.8%) | 10.37M -9.7M (-48.3%) | 0.92% -0.736 pp | 0.01% -0.012 pp | USD13.59 -11.1% | 16 qtrs — |
| 29 | WOODLINE PARTNERS LP | 845.4K +118.0 (+0.0%) | 10.21M -1.3M (-11.1%) | 0.91% -0.043 pp | 0.04% -0.015 pp | USD3.54 +241.2% | 4 qtrs — |
| 30 | NANTAHALA CAPITAL MANAGEMENT, LLC | 835.7K -100.0K (-10.7%) | 10.10M -2.6M (-20.6%) | 0.90% -0.154 pp | 0.33% -0.108 pp | USD3.40 +255.3% | 6 qtrs — |
| 31 | BOXER CAPITAL MANAGEMENT, LLC | 800.0K -100.0K (-11.1%) | 9.66M -2.6M (-21.0%) | 0.86% -0.153 pp | 2.12% -1.783 pp | USD3.78 +219.6% | 5 qtrs — |
| 32 | DIMENSIONAL FUND ADVISORS LP | 771.2K +261.5K (+51.3%) | 9.32M +2.4M (+34.3%) | 0.83% +0.254 pp | 0.00% +0.001 pp | USD9.16 +31.9% | 5 qtrs — |
| 33 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 713.0K +67.8K (+10.5%) | 8.61M -155.1K (-1.8%) | 0.76% +0.040 pp | 0.00% 0.000 pp | USD12.64 -4.4% | 16 qtrs — |
| 34 | STEMPOINT CAPITAL LP | 565.1K +288.3K (+104.1%) | 6.83M +3.1M (+81.5%) | 0.61% +0.295 pp | 1.17% +0.417 pp | USD12.82 -5.8% | 2 qtrs — |
| 35 | UBS GROUP AG | 543.3K -861.1K (-61.3%) | 6.56M -12.5M (-65.6%) | 0.58% -0.994 pp | 0.00% -0.002 pp | USD4.68 +158.1% | 16 qtrs — |
| 36 | SOFINNOVA INVESTMENTS, INC. | 527.1K +527.1K (+100.0%) | 6.37M +6.4M (+100.0%) | 0.56% +0.565 pp | 0.27% +0.275 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 37 | SILVERARC CAPITAL MANAGEMENT, LLC | 506.2K -193.8K (-27.7%) | 6.12M -3.4M (-35.7%) | 0.54% -0.243 pp | 0.85% -0.434 pp | USD13.59 -11.1% | 2 qtrs — |
| 38 | AMERIPRISE FINANCIAL INC | 502.4K +368.9K (+276.3%) | 6.07M +4.3M (+234.5%) | 0.54% +0.389 pp | 0.00% +0.001 pp | USD11.05 +9.3% | 5 qtrs — |
| 39 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 499.8K +— (+0.0%) | 6.04M -754.6K (-11.1%) | 0.54% -0.025 pp | 0.31% -0.087 pp | USD4.44 +172.1% | 4 qtrs — |
| 40 | FEDERATED HERMES, INC. | 457.4K +245.0K (+115.4%) | 5.53M +2.6M (+91.4%) | 0.49% +0.252 pp | 0.01% +0.004 pp | USD14.02 -13.8% | 14 qtrs — |
| 41 | QUBE RESEARCH & TECHNOLOGIES LTD | 412.9K +245.8K (+147.1%) | 4.99M +2.7M (+119.6%) | 0.44% +0.255 pp | 0.01% +0.003 pp | USD9.21 +31.2% | 12 qtrs — |
| 42 | CORMORANT ASSET MANAGEMENT, LP | 400.0K -100.0K (-20.0%) | 4.83M -2.0M (-28.9%) | 0.43% -0.132 pp | 0.22% -0.245 pp | USD13.59 -11.1% | 2 qtrs — |
| 43 | PARKMAN HEALTHCARE PARTNERS LLC | 381.8K -197.4K (-34.1%) | 4.61M -3.3M (-41.4%) | 0.41% -0.241 pp | 0.44% -0.382 pp | USD6.41 +88.5% | 3 qtrs — |
| 44 | PATIENT SQUARE CAPITAL LP | 350.0K +33.7K (+10.7%) | 4.23M -70.7K (-1.6%) | 0.38% +0.020 pp | 0.91% -0.245 pp | USD13.44 -10.1% | 2 qtrs — |
| 45 | CITADEL ADVISORS LLC | 345.0K +110.3K (+47.0%) | 4.17M +978.0K (+30.7%) | 0.37% +0.106 pp | 0.00% +0.000 pp | USD11.08 +9.0% | 16 qtrs — |
| 46 | TWO SIGMA INVESTMENTS, LP | 344.4K +246.0K (+249.9%) | 4.16M +2.8M (+211.1%) | 0.37% +0.259 pp | 0.01% +0.004 pp | USD9.60 +25.8% | 9 qtrs — |
| 47 | POINT72 ASSET MANAGEMENT, L.P. | 335.0K -2.5M (-88.0%) | 4.05M -33.9M (-89.3%) | 0.36% -2.771 pp | 0.00% -0.059 pp | USD5.83 +107.2% | 15 qtrs — |
| 48 | ACUTA CAPITAL PARTNERS, LLC | 333.3K +— (+0.0%) | 4.03M -503.2K (-11.1%) | 0.36% -0.017 pp | 2.73% -1.947 pp | USD13.59 -11.1% | 2 qtrs — |
| 49 | TWO SIGMA ADVISERS, LP | 328.4K +185.4K (+129.7%) | 3.97M +2.0M (+104.1%) | 0.35% +0.191 pp | 0.01% +0.004 pp | USD8.19 +47.5% | 8 qtrs — |
| 50 | ALPHA WAVE GLOBAL, LP | 317.7K -9.6K (-2.9%) | 3.84M -610.6K (-13.7%) | 0.34% -0.027 pp | 0.47% +0.020 pp | USD5.76 +109.7% | 6 qtrs — |
| 51 | BARCLAYS PLC | 295.2K +210.6K (+249.0%) | 3.57M +3.3M (+1,201.3%) | 0.32% +0.221 pp | 0.00% +0.001 pp | USD10.69 +13.0% | 16 qtrs — |
| 52 | NUVEEN, LLC | 283.9K +123.5K (+77.0%) | 3.43M +1.2M (+57.3%) | 0.30% +0.124 pp | 0.00% +0.000 pp | USD9.00 +34.2% | 3 qtrs — |
| 53 | TFG ASSET MANAGEMENT GP LTD | 272.8K +14.6K (+5.6%) | 3.30M -213.7K (-6.1%) | 0.29% +0.003 pp | 0.69% +0.226 pp | USD7.75 +55.9% | 3 qtrs — |
| 54 | JANE STREET GROUP, LLC | 263.2K +263.2K (+100.0%) | 3.18M +3.2M (+100.0%) | 0.28% +0.282 pp | 0.00% +0.001 pp | USD12.08 +0.0% | 16 qtrs — |
| 55 | ACADIAN ASSET MANAGEMENT LLC | 254.3K -113.0K (-30.8%) | 3.07M -1.9M (-38.5%) | 0.27% -0.140 pp | 0.01% -0.004 pp | USD4.67 +158.7% | 7 qtrs — |
| 56 | HIGHVISTA STRATEGIES LLC | 238.8K +238.8K (+100.0%) | 2.88M +2.9M (+100.0%) | 0.26% +0.256 pp | 0.74% +0.743 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 57 | WELLINGTON MANAGEMENT GROUP LLP | 225.8K -10.4K (-4.4%) | 2.73M -482.5K (-15.0%) | 0.24% -0.023 pp | 0.00% 0.000 pp | USD3.71 +225.6% | 5 qtrs — |
| 58 | SUMMITTX CAPITAL, L.P. | 218.4K +50.4K (+30.0%) | 2.64M +355.1K (+15.6%) | 0.23% +0.046 pp | 0.08% -0.015 pp | USD13.24 -8.8% | 2 qtrs — |
| 59 | BANK OF NEW YORK MELLON CORP | 217.3K +34.4K (+18.8%) | 2.63M +139.2K (+5.6%) | 0.23% +0.028 pp | 0.00% +0.000 pp | USD8.37 +44.3% | 3 qtrs — |
| 60 | ALDEBARAN CAPITAL, LLC | 198.5K -6.0K (-2.9%) | 2.40M -380.8K (-13.7%) | 0.21% -0.017 pp | 2.15% -0.402 pp | USD1.88 +542.6% | 7 qtrs — |
| 61 | RENAISSANCE TECHNOLOGIES LLC | 192.5K +172.6K (+867.3%) | 2.33M +2.1M (+759.9%) | 0.21% +0.184 pp | 0.00% +0.003 pp | USD11.23 +7.6% | 10 qtrs — |
| 62 | XTX TOPCO LTD | 189.7K +189.7K (+100.0%) | 2.29M +2.3M (+100.0%) | 0.20% +0.203 pp | 0.06% +0.060 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 63 | INVESCO LTD. | 175.9K -634.7K (-78.3%) | 2.13M -8.9M (-80.7%) | 0.19% -0.721 pp | 0.00% -0.001 pp | USD8.23 +46.8% | 4 qtrs — |
| 64 | SWISS NATIONAL BANK | 161.7K +161.7K (+100.0%) | 1.95M +2.0M (+100.0%) | 0.17% +0.173 pp | 0.00% +0.001 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 65 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 153.4K +153.4K (+100.0%) | 1.85M +1.9M (+100.0%) | 0.16% +0.164 pp | 0.01% +0.007 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 66 | WELLS FARGO & COMPANY/MN | 146.3K +52.6K (+56.2%) | 1.77M +494.2K (+38.8%) | 0.16% +0.052 pp | 0.00% +0.000 pp | USD11.21 +7.8% | 16 qtrs — |
| 67 | ATOM INVESTORS LP | 139.4K +139.4K (+100.0%) | 1.68M +1.7M (+100.0%) | 0.15% +0.149 pp | 0.13% +0.134 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 68 | BANK OF MONTREAL /CAN/ | 138.5K -5.2K (-3.6%) | 1.67M -280.2K (-14.3%) | 0.15% -0.013 pp | 0.00% 0.000 pp | USD2.26 +434.5% | 7 qtrs — |
| 69 | PFM HEALTH SCIENCES, LP | 134.5K -301.6K (-69.2%) | 1.63M -4.3M (-72.6%) | 0.14% -0.345 pp | 0.16% -0.294 pp | USD3.54 +241.2% | 4 qtrs — |
| 70 | NUMERAI GP LLC | 112.6K +45.5K (+67.7%) | 1.36M +448.2K (+49.1%) | 0.12% +0.045 pp | 0.16% +0.035 pp | USD12.98 -6.9% | 2 qtrs — |
| 71 | PRICE T ROWE ASSOCIATES INC /MD/ | 107.5K +7.1K (+7.1%) | 1.30M -66.0K (-4.8%) | 0.12% +0.003 pp | 0.00% +0.000 pp | USD11.39 +6.1% | 13 qtrs — |
| 72 | RHUMBLINE ADVISERS | 99.3K +617.0 (+0.6%) | 1.20M -141.5K (-10.6%) | 0.11% -0.004 pp | 0.00% 0.000 pp | USD6.45 +87.3% | 3 qtrs — |
| 73 | UBS ASSET MANAGEMENT AMERICAS INC | 98.8K +98.8K (+100.0%) | 1.19M +1.2M (+100.0%) | 0.11% +0.106 pp | 0.00% +0.000 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 74 | ALPS ADVISORS INC | 90.2K +90.2K (+100.0%) | 1.09M +1.1M (+100.0%) | 0.10% +0.097 pp | 0.01% +0.006 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 75 | STATE OF WISCONSIN INVESTMENT BOARD | 84.1K +70.3K (+506.4%) | 1.02M +827.9K (+439.1%) | 0.09% +0.075 pp | 0.00% +0.002 pp | USD12.33 -2.0% | 2 qtrs — |
| 76 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 79.1K +74.8K (+1,726.1%) | 955.4K +896.5K (+1,523.2%) | 0.08% +0.080 pp | 0.00% +0.001 pp | USD11.77 +2.6% | 3 qtrs — |
| 77 | CAMPBELL & CO INVESTMENT ADVISER LLC | 78.8K +54.3K (+221.7%) | 951.5K +618.7K (+186.0%) | 0.08% +0.057 pp | 0.05% +0.021 pp | USD12.55 -3.7% | 2 qtrs — |
| 78 | SQUAREPOINT OPS LLC | 76.6K +76.6K (+100.0%) | 924.9K +924.9K (+100.0%) | 0.08% +0.082 pp | 0.00% +0.001 pp | USD12.08 +0.0% | 16 qtrs — |
| 79 | D. E. SHAW & CO., INC. | 73.2K +4.3K (+6.3%) | 884.5K -51.5K (-5.5%) | 0.08% +0.001 pp | 0.00% +0.000 pp | USD15.35 -21.3% | 14 qtrs — |
| 80 | LEGAL & GENERAL GROUP PLC | 72.6K +5.4K (+8.0%) | 877.2K -36.3K (-4.0%) | 0.08% +0.002 pp | 0.00% +0.000 pp | USD12.75 -5.3% | 3 qtrs — |
| 81 | ALLIANCEBERNSTEIN L.P. | 71.5K +— (+0.0%) | 863.7K -108.0K (-11.1%) | 0.08% -0.004 pp | 0.00% +0.000 pp | USD10.52 +14.8% | 3 qtrs — |
| 82 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 68.9K +68.9K (+100.0%) | 832.2K +832.2K (+100.0%) | 0.07% +0.074 pp | 0.00% +0.000 pp | USD12.08 +0.0% | 16 qtrs — |
| 83 | JPMORGAN CHASE & CO | 66.5K +30.7K (+85.7%) | 803.9K +316.8K (+65.0%) | 0.07% +0.031 pp | 0.00% +0.000 pp | USD8.47 +42.6% | 16 qtrs — |
| 84 | RUSSELL INVESTMENTS GROUP, LTD. | 65.4K +10.0K (+18.1%) | 790.5K +37.5K (+5.0%) | 0.07% +0.008 pp | 0.00% +0.000 pp | USD12.30 -1.8% | 12 qtrs — |
| 85 | KENNONDALE CAPITAL MANAGEMENT LLC | 53.4K -55.2K (-50.8%) | 645.4K -830.7K (-56.3%) | 0.06% -0.065 pp | 0.47% -0.655 pp | USD4.92 +145.5% | 5 qtrs — |
| 86 | EAM INVESTORS, LLC | 53.3K -21.9K (-29.1%) | 643.3K -377.4K (-37.0%) | 0.06% -0.027 pp | 0.07% -0.045 pp | USD6.41 +88.5% | 3 qtrs — |
| 87 | SEI INVESTMENTS CO | 52.9K +52.9K (+100.0%) | 638.5K +638.5K (+100.0%) | 0.06% +0.057 pp | 0.00% +0.001 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 88 | METLIFE INVESTMENT MANAGEMENT, LLC | 49.7K +6.7K (+15.7%) | 599.8K +16.4K (+2.8%) | 0.05% +0.005 pp | 0.00% +0.000 pp | USD7.18 +68.2% | 3 qtrs — |
| 89 | TREXQUANT INVESTMENT LP | 48.1K -174.8K (-78.4%) | 581.2K -2.4M (-80.8%) | 0.05% -0.199 pp | 0.01% -0.026 pp | USD13.59 -11.1% | 2 qtrs — |
| 90 | MILLENNIUM MANAGEMENT LLC | 46.5K -371.3K (-88.9%) | 561.2K -5.1M (-90.1%) | 0.05% -0.419 pp | 0.00% -0.002 pp | USD6.07 +99.0% | 16 qtrs — |
| 91 | MARINER, LLC | 46.3K -1.7K (-3.5%) | 559.9K -92.8K (-14.2%) | 0.05% -0.004 pp | 0.00% 0.000 pp | USD30.00 -59.7% | 13 qtrs — |
| 92 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 41.2K +9.2K (+28.6%) | 497.3K +62.4K (+14.4%) | 0.04% +0.008 pp | 0.00% +0.000 pp | USD7.67 +57.5% | 3 qtrs — |
| 93 | CITIGROUP INC | 38.0K -51.0 (-0.1%) | 459.4K -58.1K (-11.2%) | 0.04% -0.002 pp | 0.00% +0.000 pp | USD9.04 +33.6% | 16 qtrs — |
| 94 | GSA CAPITAL PARTNERS LLP | 36.8K -15.3K (-29.5%) | 444.0K -264.0K (-37.3%) | 0.04% -0.019 pp | 0.04% -0.021 pp | USD6.04 +100.0% | 5 qtrs — |
| 95 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 35.9K +34.0K (+1,782.3%) | 433.4K +407.5K (+1,573.1%) | 0.04% +0.036 pp | 0.00% +0.001 pp | USD11.63 +3.9% | 4 qtrs — |
| 96 | FOX RUN MANAGEMENT, L.L.C. | 35.4K +35.4K (+100.0%) | 427.7K +427.7K (+100.0%) | 0.04% +0.038 pp | 0.07% +0.066 pp | USD12.08 +0.0% | 1 qtrs NEW |
| 97 | INTECH INVESTMENT MANAGEMENT LLC | 32.0K +12.5K (+64.2%) | 386.6K +121.7K (+45.9%) | 0.03% +0.012 pp | 0.00% +0.001 pp | USD8.63 +40.0% | 3 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.18
Bearish
Ratio by volume
0.48
Bearish
Buys
4
Sells
22
Shares acquired
400.0K
Shares disposed
834.1K
Cash buys
—
Cash sales
17.00
Net activity
-434,093
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-05 | Mazzariello Gina | Officer | A-Award | A | Stock Option (Right to Buy) | 111,990 | 14.10 | 1.58M | 111,990 | D | ↗ |
| 2026-03-05 | Klee Justin B. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 373,295 | 14.10 | 5.26M | 373,295 | D | ↗ |
| 2026-03-05 | FRATES JAMES M | Officer | A-Award | A | Stock Option (right to buy) | 143,985 | 14.10 | 2.03M | 143,985 | D | ↗ |
| 2026-03-05 | Cohen Joshua B | Director / Officer | A-Award | A | Common Stock | 248,865 | 0.00 | — | 3,583,548 | D | ↗ |
| 2026-03-05 | Bedrosian Camille L | Officer | A-Award | A | Stock Option (Right to Buy) | 143,985 | 14.10 | 2.03M | 143,985 | D | ↗ |
| 2026-03-02 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 6,844 | 14.52 | 99.4K | 134,430 | D | ↗ |
| 2026-03-02 | Klee Justin B. | Director / Officer | S-Sale | D | Common Stock | 29,282 | 14.47 | 423.8K | 3,334,616 | D | ↗ |
| 2026-03-02 | FRATES JAMES M | Officer | S-Sale | D | Common Stock | 7,909 | 14.52 | 114.9K | 165,638 | D | ↗ |
| 2026-03-02 | Cohen Joshua B | Director / Officer | S-Sale | D | Common Stock | 29,282 | 14.48 | 424.1K | 3,334,683 | D | ↗ |
| 2026-03-02 | Bedrosian Camille L | Officer | S-Sale | D | Common Stock | 6,461 | 14.58 | 94.2K | 169,295 | D | ↗ |
| 2026-02-23 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 3,419 | 14.14 | 48.4K | 141,274 | D | ↗ |
| 2026-02-02 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 3,448 | 14.65 | 50.5K | 144,693 | D | ↗ |
| 2026-02-02 | Klee Justin B. | Director / Officer | S-Sale | D | Common Stock | 15,500 | 14.69 | 227.6K | 3,363,898 | D | ↗ |
| 2026-02-02 | FRATES JAMES M | Officer | S-Sale | D | Common Stock | 3,557 | 14.65 | 52.1K | 173,547 | D | ↗ |
| 2026-02-02 | Cohen Joshua B | Director / Officer | S-Sale | D | Common Stock | 15,500 | 14.68 | 227.6K | 3,363,965 | D | ↗ |
| 2026-01-16 | Klee Justin B. | Director / Officer | M-Exempt | A | Common Stock | 2,847 | 7.57 | 21.6K | 3,381,393 | D | ↗ |
| 2026-01-16 | Cohen Joshua B | Director / Officer | M-Exempt | A | Common Stock | 2,818 | 7.57 | 21.3K | 3,381,439 | D | ↗ |
| 2026-01-15 | Klee Justin B. | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 197,153 | 7.57 | 1.49M | 2,847 | D | ↗ |
| 2026-01-15 | Cohen Joshua B | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 197,182 | 7.57 | 1.49M | 2,818 | D | ↗ |
| 2026-01-12 | MILNE GEORGE M JR | Director | G-Gift | D | Common Stock | 17,780 | 0.00 | — | 812,881 | D | ↗ |
| 2026-01-06 | Klee Justin B. | Director / Officer | S-Sale | D | Common Stock | 7,715 | 11.09 | 85.6K | 3,317,586 | D | ↗ |
| 2026-01-06 | FRATES JAMES M | Officer | S-Sale | D | Common Stock | 3,326 | 11.11 | 37.0K | 177,104 | D | ↗ |
| 2026-01-06 | Cohen Joshua B | Director / Officer | S-Sale | D | Common Stock | 7,715 | 11.09 | 85.6K | 3,317,632 | D | ↗ |
| 2025-12-23 | Firestone Karen | Director | P-Purchase | A | Common Stock | 8,100 | 12.45 | 100.8K | 63,100 | D | ↗ |
| 2025-12-01 | Bedrosian Camille L | Officer | S-Sale | D | Common Stock | 6,580 | 14.35 | 94.4K | 175,756 | D | ↗ |
| 2025-09-30 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 8,828 | 14.58 | 128.7K | 148,141 | D | ↗ |
| 2025-09-30 | Klee Justin B. | Director / Officer | S-Sale | D | Common Stock | 200 | 15.01 | 3.0K | 3,325,301 | D | ↗ |
| 2025-09-30 | FRATES JAMES M | Officer | S-Sale | D | Common Stock | 10,558 | 14.65 | 154.7K | 280,430 | D | ↗ |
| 2025-09-30 | Cohen Joshua B | Director / Officer | S-Sale | D | Common Stock | 200 | 15.00 | 3.0K | 3,325,347 | D | ↗ |
| 2025-09-30 | Bedrosian Camille L | Officer | S-Sale | D | Common Stock | 12,039 | 14.58 | 175.5K | 182,336 | D | ↗ |
| 2025-08-13 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 15,000 | 8.34 | 125.0K | 156,969 | D | ↗ |
| 2025-08-12 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 15,000 | 8.07 | 121.1K | 171,969 | D | ↗ |
| 2025-06-05 | Zeiher Bernhardt G | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.05 | 126.3K | 25,000 | D | ↗ |
| 2025-06-05 | Quimi Daphne | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.05 | 126.3K | 25,000 | D | ↗ |
| 2025-06-05 | MILNE GEORGE M JR | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.05 | 126.3K | 25,000 | D | ↗ |
| 2025-06-05 | Firestone Karen | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.05 | 126.3K | 25,000 | D | ↗ |
| 2025-06-05 | FONTEYNE PAUL R. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.05 | 126.3K | 25,000 | D | ↗ |
| 2025-05-22 | Mazzariello Gina | Officer | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 186,969 | D | ↗ |
| 2025-03-31 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 9,192 | 3.48 | 32.0K | 187,969 | D | ↗ |
| 2025-03-31 | Klee Justin B. | Director / Officer | S-Sale | D | Common Stock | 21,490 | 3.46 | 74.5K | 3,355,276 | D | ↗ |
| 2025-03-31 | FRATES JAMES M | Officer | S-Sale | D | Common Stock | 10,896 | 3.47 | 37.8K | 290,988 | D | ↗ |
| 2025-03-31 | Cohen Joshua B | Director / Officer | S-Sale | D | Common Stock | 21,490 | 3.47 | 74.5K | 3,355,280 | D | ↗ |
| 2025-03-31 | Bedrosian Camille L | Officer | S-Sale | D | Common Stock | 12,425 | 3.47 | 43.1K | 194,375 | D | ↗ |
| 2025-03-20 | Zeiher Bernhardt G | Director | P-Purchase | A | Common Stock | 10,000 | 3.70 | 37.0K | 10,000 | D | ↗ |
| 2025-03-06 | Mazzariello Gina | Officer | A-Award | A | Stock Option (right to buy) | 95,777 | 3.61 | 345.8K | 95,777 | D | ↗ |
| 2025-03-06 | Klee Justin B. | Director / Officer | A-Award | A | Stock Option (right to buy) | 270,177 | 3.61 | 975.3K | 270,177 | D | ↗ |
| 2025-03-06 | FRATES JAMES M | Officer | A-Award | A | Stock Option (right to buy) | 102,630 | 3.61 | 370.5K | 102,630 | D | ↗ |
| 2025-03-06 | Cohen Joshua B | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 270,177 | 3.61 | 975.3K | 270,177 | D | ↗ |
| 2025-03-06 | Bedrosian Camille L | Officer | A-Award | A | Stock Option (Right to Buy) | 102,630 | 3.61 | 370.5K | 102,630 | D | ↗ |
| 2025-03-03 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 1,611 | 3.12 | 5.0K | 133,310 | D | ↗ |
| 2025-03-03 | Klee Justin B. | Director / Officer | S-Sale | D | Common Stock | 4,595 | 3.15 | 14.5K | 3,196,648 | D | ↗ |
| 2025-03-03 | Cohen Joshua B | Director / Officer | S-Sale | D | Common Stock | 4,595 | 3.17 | 14.5K | 3,196,652 | D | ↗ |
| 2025-02-24 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 4,169 | 3.15 | 13.1K | 134,921 | D | ↗ |
| 2025-02-05 | Klee Justin B. | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 36,310 | 1.57 | 57.0K | 0 | D | ↗ |
| 2025-02-03 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 3,678 | 3.49 | 12.8K | 139,090 | D | ↗ |
| 2025-02-03 | Klee Justin B. | Director / Officer | S-Sale | D | Common Stock | 11,855 | 3.47 | 41.1K | 3,164,933 | D | ↗ |
| 2025-02-03 | Cohen Joshua B | Director / Officer | S-Sale | D | Common Stock | 11,851 | 3.47 | 41.1K | 3,201,247 | D | ↗ |
| 2025-01-24 | MILNE GEORGE M JR | Director | G-Gift | D | Common Stock | 27,910 | 0.00 | — | 830,661 | D | ↗ |
| 2025-01-06 | Klee Justin B. | Director / Officer | S-Sale | D | Common Stock | 7,471 | 4.04 | 30.2K | 3,176,788 | D | ↗ |
| 2025-01-06 | Cohen Joshua B | Director / Officer | S-Sale | D | Common Stock | 7,471 | 4.05 | 30.2K | 3,213,098 | D | ↗ |
| 2024-12-02 | Bedrosian Camille L | Officer | S-Sale | D | Common Stock | 5,421 | 5.54 | 30.0K | 138,380 | D | ↗ |
| 2024-11-04 | Klee Justin B. | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 63,690 | 1.57 | 100.0K | 36,310 | D | ↗ |
| 2024-09-30 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 8,709 | 3.20 | 27.8K | 142,768 | D | ↗ |
| 2024-09-30 | Klee Justin B. | Director / Officer | S-Sale | D | Common Stock | 18,589 | 3.20 | 59.4K | 3,120,569 | D | ↗ |
| 2024-09-30 | Cohen Joshua B | Director / Officer | S-Sale | D | Common Stock | 18,589 | 3.20 | 59.4K | 3,220,569 | D | ↗ |
| 2024-09-30 | Bedrosian Camille L | Officer | S-Sale | D | Common Stock | 11,442 | 3.20 | 36.6K | 143,801 | D | ↗ |
| 2024-09-23 | Cohen Joshua B | Director / Officer | M-Exempt | A | Common Stock | 1,857 | 1.57 | 2.9K | 3,239,158 | D | ↗ |
| 2024-09-12 | FRATES JAMES M | Officer | P-Purchase | A | Common Stock | 40,000 | 2.53 | 101.4K | 233,464 | — | ↗ |
| 2024-09-12 | Cohen Joshua B | Director / Officer | M-Exempt | A | Common Stock | 34,449 | 1.57 | 54.1K | 3,237,301 | — | ↗ |
| 2024-09-05 | Firestone Karen | Director | P-Purchase | A | Common Stock | 50,000 | 2.13 | 106.6K | 55,000 | — | ↗ |
| 2024-09-03 | MILNE GEORGE M JR | Director | P-Purchase | A | Common Stock | 100,000 | 2.20 | 219.8K | 858,571 | — | ↗ |
| 2024-06-06 | Zeiher Bernhardt G | Director | A-Award | A | Stock Option (right to buy) | 5,753 | 1.76 | 10.1K | 5,753 | — | ↗ |
| 2024-06-06 | Quimi Daphne | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.76 | 44.0K | 25,000 | — | ↗ |
| 2024-06-06 | MILNE GEORGE M JR | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.76 | 44.0K | 25,000 | — | ↗ |
| 2024-06-06 | Firestone Karen | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.76 | 44.0K | 25,000 | — | ↗ |
| 2024-06-06 | FONTEYNE PAUL R. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.76 | 44.0K | 25,000 | — | ↗ |
| 2024-05-15 | Quimi Daphne | Director | P-Purchase | A | Common Stock | 2,250 | 1.89 | 4.3K | 5,000 | — | ↗ |
| 2024-05-15 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 10,455 | 1.88 | 19.7K | 151,477 | — | ↗ |
| 2024-05-14 | Quimi Daphne | Director | P-Purchase | A | Common Stock | 2,750 | 1.89 | 5.2K | 2,750 | — | ↗ |
| 2024-04-16 | Mazzariello Gina | Officer | A-Award | A | Common Stock | 80,560 | 0.00 | — | 161,932 | — | ↗ |
| 2024-04-16 | Klee Justin B. | Director / Officer | A-Award | A | Stock Option (right to buy) | 380,000 | 2.01 | 763.8K | 380,000 | — | ↗ |
| 2024-04-16 | FRATES JAMES M | Officer | A-Award | A | Common Stock | 91,180 | 0.00 | — | 225,964 | — | ↗ |
| 2024-04-16 | Cohen Joshua B | Director / Officer | A-Award | A | Stock Option (right to buy) | 380,000 | 2.01 | 763.8K | 380,000 | — | ↗ |
| 2024-04-16 | Bedrosian Camille L | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 2.01 | 241.2K | 120,000 | — | ↗ |
| 2024-03-14 | Zeiher Bernhardt G | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 3.17 | 158.5K | 50,000 | — | ↗ |
| 2024-03-05 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 1,540 | 18.73 | 28.8K | 81,372 | — | ↗ |
| 2024-03-05 | Klee Justin B. | Director / Officer | S-Sale | D | Common Stock | 4,135 | 18.73 | 77.4K | 2,959,308 | — | ↗ |
| 2024-03-05 | FRATES JAMES M | Officer | S-Sale | D | Common Stock | 1,792 | 18.73 | 33.6K | 134,784 | — | ↗ |
| 2024-03-05 | Cohen Joshua B | Director / Officer | S-Sale | D | Common Stock | 4,135 | 18.73 | 77.4K | 3,023,002 | — | ↗ |
| 2024-02-26 | Mazzariello Gina | Officer | A-Award | A | Common Stock | 36,667 | 0.00 | — | 82,912 | — | ↗ |
| 2024-02-26 | Klee Justin B. | Director / Officer | A-Award | A | Stock Option (right to buy) | 190,000 | 17.56 | 3.34M | 190,000 | — | ↗ |
| 2024-02-26 | FRATES JAMES M | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 152,035 | — | ↗ |
| 2024-02-26 | Cohen Joshua B | Director / Officer | A-Award | A | Stock Option (right to buy) | 190,000 | 17.56 | 3.34M | 190,000 | — | ↗ |
| 2024-02-23 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 2,838 | 18.76 | 53.2K | 46,245 | — | ↗ |
| 2024-01-25 | MILNE GEORGE M JR | Director | G-Gift | D | Common Stock | 9,100 | 0.00 | — | 758,571 | — | ↗ |
| 2024-01-16 | MILNE GEORGE M JR | Director | G-Gift | D | Common Stock | 94,350 | 0.00 | — | 767,671 | — | ↗ |
| 2024-01-09 | Yeramian Patrick D | Officer | S-Sale | D | Common Stock | 2,812 | 16.33 | 45.9K | 205,605 | — | ↗ |
| 2024-01-09 | Klee Justin B. | Director / Officer | S-Sale | D | Common Stock | 5,841 | 16.33 | 95.4K | 2,836,776 | — | ↗ |
| 2024-01-09 | FRATES JAMES M | Officer | S-Sale | D | Common Stock | 2,716 | 16.33 | 44.3K | 112,035 | — | ↗ |
| 2024-01-09 | Cohen Joshua B | Director / Officer | S-Sale | D | Common Stock | 5,841 | 16.33 | 95.4K | 2,900,470 | — | ↗ |
| 2023-12-27 | Olinger Margaret | Officer | M-Exempt | A | Common Stock | 25,000 | 0.37 | 9.3K | 276,108 | — | ↗ |
| 2023-12-15 | Firestone Karen | Director | P-Purchase | A | Common Stock | 4,000 | 14.97 | 59.9K | 5,000 | — | ↗ |
| 2023-11-27 | Bedrosian Camille L | Officer | A-Award | A | Stock Option (Right to Buy) | 162,500 | 12.93 | 2.10M | 162,500 | — | ↗ |
| 2023-11-16 | Cohen Joshua B | Director / Officer | M-Exempt | A | Common Stock | 63,694 | 1.57 | 100.0K | 2,906,311 | — | ↗ |
| 2023-10-31 | FRATES JAMES M | Officer | G-Gift | A | Common Stock | 11,072 | 0.00 | — | 11,072 | — | ↗ |
| 2023-08-23 | FRATES JAMES M | Officer | M-Exempt | A | Common Stock | 18,165 | 6.88 | 125.0K | 73,841 | — | ↗ |
| 2023-08-15 | Morningside Venture Investments Ltd | 10% Owner | G-Gift | D | Common Stock | 2,000,000 | 0.00 | — | 4,997,302 | — | ↗ |
| 2023-08-15 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 6,164 | 20.88 | 128.7K | 49,083 | — | ↗ |
| 2023-07-12 | Olinger Margaret | Officer | M-Exempt | A | Common Stock | 20,000 | 0.37 | 7.4K | 251,108 | — | ↗ |
| 2023-06-08 | Quimi Daphne | Director | A-Award | A | Stock Option (right to buy) | 16,985 | 26.25 | 445.9K | 16,985 | — | ↗ |
| 2023-06-08 | MILNE GEORGE M JR | Director | A-Award | A | Stock Option (right to buy) | 16,985 | 26.25 | 445.9K | 16,985 | — | ↗ |
| 2023-06-08 | Firestone Karen | Director | A-Award | A | Stock Option (right to buy) | 3,908 | 26.25 | 102.6K | 3,908 | — | ↗ |
| 2023-06-08 | FONTEYNE PAUL R. | Director | A-Award | A | Stock Option (right to buy) | 16,985 | 26.25 | 445.9K | 16,985 | — | ↗ |
| 2023-05-22 | Olinger Margaret | Officer | G-Gift | D | Common Stock | 1,580 | 0.00 | — | 231,108 | — | ↗ |
| 2023-05-17 | Mazzariello Gina | Officer | G-Gift | D | Common Stock | 500 | 0.00 | — | 55,247 | — | ↗ |
| 2023-05-16 | FRATES JAMES M | Officer | S-Sale | D | Common Stock | 32,000 | 26.93 | 861.7K | 56,176 | — | ↗ |
| 2023-05-15 | Yeramian Patrick D | Officer | M-Exempt | A | Common Stock | 9,764 | 6.88 | 67.2K | 220,382 | — | ↗ |
| 2023-04-17 | Yeramian Patrick D | Officer | M-Exempt | A | Common Stock | 44,861 | 0.37 | 16.6K | 253,278 | — | ↗ |
| 2023-03-29 | Morningside Venture Investments Ltd | 10% Owner | S-Sale | D | Common Stock | 29,048 | 30.45 | 884.5K | 6,997,302 | — | ↗ |
| 2023-03-28 | Morningside Venture Investments Ltd | 10% Owner | S-Sale | D | Common Stock | 100,000 | 30.37 | 3.04M | 7,026,350 | — | ↗ |
| 2023-03-27 | Morningside Venture Investments Ltd | 10% Owner | S-Sale | D | Common Stock | 32,964 | 30.25 | 997.2K | 7,154,350 | — | ↗ |
| 2023-03-21 | Morningside Venture Investments Ltd | 10% Owner | S-Sale | D | Common Stock | 28,807 | 32.17 | 926.7K | 7,187,314 | — | ↗ |
| 2023-03-16 | Yeramian Patrick D | Officer | A-Award | A | Common Stock | 9,167 | 0.00 | — | 158,839 | — | ↗ |
| 2023-03-16 | Olinger Margaret | Officer | A-Award | A | Stock Option (right to buy) | 82,500 | 32.08 | 2.65M | 82,500 | — | ↗ |
| 2023-03-16 | Morningside Venture Investments Ltd | 10% Owner | S-Sale | D | Common Stock | 9,122 | 32.55 | 296.9K | 7,250,762 | — | ↗ |
| 2023-03-16 | Mazzariello Gina | Officer | A-Award | A | Common Stock | 18,333 | 0.00 | — | 55,747 | — | ↗ |
| 2023-03-16 | MILNE GEORGE M JR | Director | S-Sale | D | Common Stock | 33,084 | 31.86 | 1.05M | 863,937 | — | ↗ |
| 2023-03-16 | Klee Justin B. | Director / Officer | A-Award | A | Stock Option (right to buy) | 225,000 | 32.08 | 7.22M | 225,000 | — | ↗ |
| 2023-03-16 | Firestone Karen | Director | P-Purchase | A | Common Stock | 1,000 | 31.99 | 32.0K | 1,000 | — | ↗ |
| 2023-03-16 | FRATES JAMES M | Officer | A-Award | A | Common Stock | 21,667 | 0.00 | — | 23,176 | D | ↗ |
| 2023-03-16 | Cohen Joshua B | Director / Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 2,842,617 | — | ↗ |
| 2023-03-15 | Morningside Venture Investments Ltd | 10% Owner | S-Sale | D | Common Stock | 41,066 | 33.68 | 1.38M | 7,259,884 | — | ↗ |
| 2023-03-14 | Morningside Venture Investments Ltd | 10% Owner | S-Sale | D | Common Stock | 70,714 | 34.54 | 2.44M | 7,409,884 | — | ↗ |
| 2023-03-02 | Morningside Venture Investments Ltd | 10% Owner | S-Sale | D | Common Stock | 50,000 | 33.75 | 1.69M | 7,480,598 | — | ↗ |
| 2023-02-24 | Mazzariello Gina | Officer | S-Sale | D | Common Stock | 3,586 | 34.49 | 123.7K | 37,414 | — | ↗ |
| 2023-02-23 | Morningside Venture Investments Ltd | 10% Owner | S-Sale | D | Common Stock | 48,889 | 35.55 | 1.74M | 7,581,709 | — | ↗ |
| 2023-02-22 | Morningside Venture Investments Ltd | 10% Owner | S-Sale | D | Common Stock | 47,888 | 34.70 | 1.66M | 7,532,710 | — | ↗ |
| 2023-01-06 | Yeramian Patrick D | Officer | S-Sale | A | Common Stock | 1,405 | 36.08 | 50.7K | 204,928 | — | ↗ |
| 2023-01-06 | Olinger Margaret | Officer | S-Sale | A | Common Stock | 743 | 36.79 | 27.3K | 214,355 | — | ↗ |
| 2023-01-06 | Klee Justin B. | Officer | S-Sale | A | Common Stock | 1,846 | 36.79 | 67.9K | 2,892,617 | — | ↗ |
| 2023-01-06 | FRATES JAMES M | Officer | S-Sale | A | Common Stock | 822 | 36.79 | 30.2K | 34,009 | — | ↗ |
| 2023-01-06 | Cohen Joshua B | Officer | S-Sale | A | Common Stock | 1,846 | 36.79 | 67.9K | 2,892,617 | — | ↗ |
| 2022-12-31 | Morningside Venture Investments Ltd | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-30 | FRATES JAMES M | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 0.00 | — | 447,000 | — | ↗ |
| 2022-11-11 | VIKING GLOBAL INVESTORS LP | — | C-Conversion | D | Series C-1 Preferred Stock | 4,870,536 | 0.00 | — | 0 | — | ↗ |
| 2022-07-06 | ALS Invest 1 B.V. | Director | S-Sale | D | Common Stock | 18,312 | 19.54 | 357.8K | 5,937,577 | — | ↗ |
| 2022-06-09 | Quimi Daphne | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-06-09 | MILNE GEORGE M JR | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-06-09 | FONTEYNE PAUL R. | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-06-09 | Cheng Isaac | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-05-05 | Klee Justin B. | Officer | M-Exempt | D | Stock Option (right to buy) | 334,520 | 0.00 | — | 0 | — | ↗ |
| 2022-05-05 | Cohen Joshua B | Officer | M-Exempt | D | Stock Option (right to buy) | 334,520 | 0.00 | — | 0 | — | ↗ |
| 2022-02-22 | Mazzariello Gina | Officer | A-Award | A | Common Stock | 41,000 | 0.00 | — | 41,000 | — | ↗ |
| 2022-02-11 | FRATES JAMES M | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 19.63 | 490.6K | 25,000 | — | ↗ |
| 2022-01-11 | VIKING GLOBAL INVESTORS LP | — | P-Purchase | A | Common Stock | 2,300,000 | 19.00 | 43.70M | 2,300,000 | — | ↗ |
| 2022-01-11 | Morningside Venture Investments Ltd | 10% Owner | C-Conversion | D | Series A Preferred Stock | 1,409,035 | 0.00 | — | 0 | — | ↗ |
| 2022-01-11 | DRAGSA 96 LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,300,000 | — | ↗ |
| 2022-01-11 | ALS Invest 1 B.V. | 10% Owner | C-Conversion | A | Common Stock | 4,826,503 | 0.00 | — | 5,955,889 | — | ↗ |
| 2022-01-06 | Yeramian Patrick D | Officer | — | D | Stock Option (Right to Buy) | 2,789 | 0.33 | 920.37 | 0 | — | ↗ |
| 2022-01-06 | VIKING GLOBAL INVESTORS LP | — | — | I | Series C-1 Preferred Stock | 4,870,536 | 0.00 | — | 0 | — | ↗ |
| 2022-01-06 | Quimi Daphne | Director | — | D | Stock Option (Right to Buy) | 81,100 | 7.09 | 575.0K | 0 | — | ↗ |
| 2022-01-06 | Olinger Margaret | Officer | A-Award | A | Stock Option (right to buy) | 127,500 | 19.00 | 2.42M | 127,500 | — | ↗ |
| 2022-01-06 | Morningside Venture Investments Ltd | 10% Owner | — | D | Series A Preferred Stock | 1,409,035 | 0.00 | — | 0 | — | ↗ |
| 2022-01-06 | MILNE GEORGE M JR | Director | — | D | Common Stock | 0 | 0.00 | — | 195,081 | — | ↗ |
| 2022-01-06 | Klee Justin B. | Director / Officer | A-Award | A | Stock Option (right to buy) | 337,500 | 19.00 | 6.41M | 337,500 | — | ↗ |
| 2022-01-06 | FRATES JAMES M | Officer | — | D | Stock Option (Right to Buy) | 452,000 | 6.88 | 3.11M | 0 | — | ↗ |
| 2022-01-06 | FONTEYNE PAUL R. | Director | — | D | Stock Option (Right to Buy) | 81,100 | 6.88 | 558.0K | 0 | — | ↗ |
| 2022-01-06 | Cohen Joshua B | Director / Officer | — | D | Series C-1 Preferred Stock | 4,870 | 0.00 | — | 0 | — | ↗ |
| 2022-01-06 | Cheng Isaac | Director | — | I | Series B Preferred Stock | 6,410,964 | 0.00 | — | 0 | — | ↗ |
| 2022-01-06 | ALS Invest 1 B.V. | 10% Owner | — | D | Series B Preferred Stock | 4,826,503 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
83.13M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Justin Klee Co-Chief Executive Officer and Director | 686.2K | — | 650.2K | 817.8K | 548.1K | 17.5K | 2.72M | 53.97% | ↗ |
| 2 | 2025 | Joshua Cohen Co-Chief Executive Officer and Director | 686.2K | — | 650.2K | 817.8K | 548.1K | 17.5K | 2.72M | 53.97% | ↗ |
| 3 | 2025 | Camille L. Bedrosian, M.D. Chief Medical Officer | 575.0K | — | 247.0K | 312.9K | 275.6K | 157.2K | 1.57M | 35.71% | ↗ |
| 4 | 2025 | James Frates Chief Financial Officer | 540.6K | — | 247.0K | 311.1K | 259.1K | 17.5K | 1.38M | 40.58% | ↗ |
| 5 | 2024 | Joshua Cohen Co-Chief Executive Officer and Director | 686.2K | — | 2.59M | 2.69M | 521.9K | 17.3K | 6.50M | 81.14% | ↗ |
| 6 | 2024 | Justin Klee Co-Chief Executive Officer and Director | 686.2K | — | 2.59M | 2.69M | 521.9K | 17.3K | 6.50M | 81.14% | ↗ |
| 7 | 2024 | James Frates Chief Financial Officer | 540.6K | — | 885.7K | 848.4K | 248.4K | 17.3K | 2.54M | 68.26% | ↗ |
| 8 | 2024 | Gina M. Mazzariello Chief Legal Officer and General Counsel | 478.4K | — | 805.8K | 777.7K | 219.8K | 17.3K | 2.30M | 68.88% | ↗ |
| 9 | 2023 | Joshua Cohen Co-Chief Executive Officer and Director | 621.0K | — | 1.60M | 4.73M | 447.7K | 11.5K | 7.42M | 85.44% | ↗ |
| 10 | 2023 | Justin Klee Co-Chief Executive Officer and Director | 621.0K | — | 1.60M | 4.73M | 447.7K | 11.5K | 7.42M | 85.44% | ↗ |
| 11 | 2023 | James Frates Chief Financial Officer | 510.0K | — | 695.1K | 2.05M | 241.7K | 11.5K | 3.51M | 78.26% | ↗ |
| 12 | 2023 | Margaret Olinger Former Chief Commercial Officer | 488.8K | — | 618.2K | 1.74M | 225.2K | 378.1K | 3.45M | 68.32% | ↗ |
| 13 | 2023 | Gina M. Mazzariello Chief Legal Officer and General Counsel | 460.0K | — | 588.1K | 1.74M | 217.8K | 11.5K | 3.01M | 77.13% | ↗ |
| 14 | 2023 | Camille L. Bedrosian, M.D. Chief Medical Officer | 56.8K | 173.0K | 754.2K | 1.39M | — | 2.8K | 2.37M | 90.20% | ↗ |
| 15 | 2022 | Joshua Cohen Co-Chief Executive Officer and Director | 539.3K | — | 1.43M | 4.75M | 453.0K | 9.2K | 7.18M | 86.05% | ↗ |
| 16 | 2022 | Justin Klee Co-Chief Executive Officer and Director | 539.3K | — | 1.43M | 4.75M | 453.0K | 9.2K | 7.18M | 86.05% | ↗ |
| 17 | 2022 | Gina M. Mazzariello Chief Legal Officer and General Counsel | 342.6K | 250.0K | 1.23M | 4.09M | 193.1K | 9.2K | 6.11M | 87.00% | ↗ |
| 18 | 2022 | James Frates Chief Financial Officer | 439.5K | — | 601.7K | 2.36M | 246.5K | 9.2K | 3.66M | 81.00% | ↗ |
| 19 | 2022 | Margaret Olinger Former Chief Commercial Officer | 424.3K | — | 538.3K | 1.80M | 228.8K | 9.2K | 3.00M | 77.89% | ↗ |
| 20 | 2021 | James Frates Chief Financial Officer | 375.0K | 615.0K | — | 2.05M | 205.1K | 8.7K | 3.26M | 63.03% | ↗ |
| 21 | 2021 | Justin Klee Co-Chief Executive Officer and Director | 417.8K | — | — | 698.0K | 300.0K | 8.7K | 1.42M | 49.00% | ↗ |
| 22 | 2021 | Joshua Cohen Co-Chief Executive officer and Director | 417.8K | — | — | 698.0K | 300.0K | 8.7K | 1.42M | 49.00% | ↗ |
| 23 | 2021 | Joshua Cohen Co-Chief Executive Officer and Director | 417.8K | — | — | 698.0K | 300.0K | 8.7K | 1.42M | 49.00% | ↗ |
| 24 | 2021 | Margaret Olinger Chief Commercial Officer | 372.0K | — | — | 296.4K | 186.3K | 8.7K | 863.4K | 34.33% | ↗ |
| 25 | 2021 | Margaret Olinger Former Chief Commercial Officer | 372.0K | — | — | 296.4K | 186.3K | 8.7K | 863.4K | 34.33% | ↗ |
| 26 | 2020 | Justin Klee Co-Chief Executive Officer and Director | 370.0K | — | — | 97.0K | 203.5K | — | 670.5K | 14.47% | ↗ |
| 27 | 2020 | Joshua Cohen Co-Chief Executive officer and Director | 370.0K | — | — | 97.0K | 203.5K | — | 670.5K | 14.47% | ↗ |
| 28 | 2020 | Margaret Olinger Chief Commercial Officer | 360.2K | — | — | — | 154.8K | — | 515.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joshua Cohen | Co-Founder, Co-CEO & Director | 1M | male |
| Justin Klee | Co-Founder, Co-CEO & Director | 1M | male |
| Camille L. Bedrosian | Chief Medical Officer | 1M | — |
| James Frates | Chief Financial Officer | 817.2K | male |
| Gina Mazzariello | Chief Legal Officer & General Counsel | 715.5K | female |
| Dan Monahan | Chief Commercial Officer | — | male |
| Linda A. Arsenault | Chief Human Resources Officer | — | female |
| Lindsey Allen | Head of Investor Relations & Communications | — | female |
| Machelle Manuel | Vice President & Head of Global Medical Affairs | — | — |
| Tammy Sarnelli | Global Head of Regulatory Affairs | — | female |
| Tom Holmes | Chief Technical Operations Officer | — | male |
| Jamie Timmons | Head of Global Medical Strategy & Communications | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2022-10-12 | 2022-11-16 | Christopher L. Jacobs | NY27 | — | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AMLX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
